Aspira Women’s Health Announces 1-for-15 Reverse Stock Split
2023年5月12日 - 1:33AM
Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a
bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic, tools, today
announced a 1-for-15 reverse stock split of its outstanding common
stock, effective at 12:01 am Eastern time on May 11, 2023.
Beginning tomorrow, May 12, 2023, the Company’s common stock will
trade on a split-adjusted basis.
At the Company’s Annual Meeting of Stockholders meeting held on
May 9, 2023, the Company’s stockholders approved a proposal to its
Amended and Restated Certificate of Incorporation to effect a
reverse stock split of its outstanding shares of common stock, par
value $0.001 per share, by a ratio of any whole number between
1-for-10 to 1-for-20, the implementation and timing of which was
subject to the discretion of the Company’s Board of Directors. On
May 9, 2023, the Board of Directors approved a 1-for-15 reverse
split, and on May 11, 2023, the Company filed a Certificate of
Amendment to its Amended and Restated Certificate of Incorporation
to affect the reverse stock split.
The Company’s Board of Directors implemented the reverse stock
split with the objective of regaining compliance with the $1.00
minimum bid price requirement of The Nasdaq Capital Market. To
comply with this requirement, the closing bid of the Company’s
common stock must be at least $1.00 per share for a minimum of 10
consecutive business days prior to May 29, 2023. The Company has
until May 29, 2023, to comply with this requirement.
The Company’s shares of common stock will continue to trade on
the NASDAQ under the symbol “AWH.” The new CUSIP number for the
Company’s common stock post-reverse stock split is 04537Y 208.
Upon the effectiveness of the reverse stock split, every 15
shares of the Company’s issued and outstanding common stock will
automatically be converted into one share of common stock. Any
fraction of a share of common stock that would be created as a
result of the reverse stock split will be paid out.
About Aspira Women’s Health Inc.Aspira
Women’s Health Inc. is transforming women’s gynecological health
with the discovery, development, and commercialization of
innovative testing options for women of all races and
ethnicities.
Our ovarian cancer risk assessment portfolio is marketed to
healthcare providers as OvaSuiteSM. OvaWatchSM is a
non-invasive, blood-based test intended for use in the initial
clinical assessment of ovarian cancer risk in women with benign or
indeterminate adnexal masses for which surgical intervention may be
either premature or unnecessary. With a negative predictive value
(NPV) of 99%, OvaWatch allows physicians to confidently rule out
ovarian cancer malignancy and choose the appropriate clinical
management for the right patient at the right time.
Ova1Plus® combines our FDA-cleared products, Ova1® and
OVERA®, to detect risk of ovarian malignancy in women with adnexal
masses planned for surgery.
EndoCheck™, Aspira’s first-of-its-kind non-invasive diagnostic
test for endometriosis, is currently in development. Visit our
website for more information
at www.aspirawh.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, as defined in
the Private Securities Litigation Reform Act of 1995, including
statements regarding the potential effects of widespread use of
OvaWatch and the availability of OvaWatch in New York.
Forward-looking statements involve a number of risks and
uncertainties. Words such as “may,” “expects,” “intends,”
“anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,”
“should,” “continue,” “will,” “potential,” “projects” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions, including those described in the section entitled
“Risk Factors” in Aspira’s Annual Report on Form 10-K for the year
ended December 31, 2022. These risks include, but are not limited
to: our ability to continue as a going concern; our ability to
comply with Nasdaq’s continued listing requirements; impacts
resulting from potential changes to coverage of Ova1 through our
Medicare Administrative Carrier for Ova1; impacts resulting from or
relating to the COVID-19 pandemic and actions taken to contain it;
anticipated use of capital and its effects; our ability to increase
the volume of our product sales; failures by third-party payers to
reimburse for our products and services or changes to reimbursement
rates; our ability to continue developing existing technologies and
to develop, protect and promote our proprietary technologies; plans
to develop and perform laboratory developed tests; our ability to
comply with Food and Drug Administration (“FDA”) regulations that
relate to our products and to obtain any FDA clearance or approval
required to develop and commercialize medical devices; our ability
to develop and commercialize additional diagnostic products and
achieve market acceptance with respect to these products; our
ability to compete successfully; our ability to obtain any
regulatory approval required for our future diagnostic products; or
our suppliers’ ability to comply with FDA requirements for
production, marketing and post-market monitoring of our products;
our ability to maintain sufficient or acceptable supplies of
immunoassay kits from our suppliers; in the event that we succeed
in commercializing our products outside the United States, the
political, economic and other conditions affecting other countries;
changes in healthcare policy; our ability to comply with the
additional laws and regulations that apply to us in connection with
the operation of ASPIRA LABS; our ability to use our net operating
loss carryforwards; our ability to use intellectual property; our
ability to successfully defend our proprietary technology against
third parties; our ability to obtain licenses in the event a third
party successfully asserts proprietary rights; the liquidity and
trading volume of our common stock; the concentration of ownership
of our common stock; our ability to retain key employees; our
ability to secure additional capital on acceptable terms to execute
our business plan; business interruptions; the effectiveness and
availability of our information systems; our ability to integrate
and achieve anticipated results from any acquisitions or strategic
alliances; future litigation against us, including infringement of
intellectual property and product liability exposure; and
additional costs that may be required to make further improvements
to our laboratory operations. The events and circumstances
reflected in Aspira’s forward-looking statements may not be
achieved or occur, and actual results could differ materially from
those projected in the forward-looking statements. Aspira expressly
disclaims any obligation to update, amend or clarify any
forward-looking statements whether as a result of new information,
future events or otherwise, except as required by law.
Investor Relations
Contact:Monique Kosse Managing DirectorLifeSci Advisors,
LLCTel: 212-915-3820
Aspira Womans Health (NASDAQ:AWH)
過去 株価チャート
から 6 2024 まで 7 2024
Aspira Womans Health (NASDAQ:AWH)
過去 株価チャート
から 7 2023 まで 7 2024